Skip to content

Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery

Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery (Randomized, Pilot Study)

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03183596
Enrollment
0
Registered
2017-06-12
Start date
2019-12-31
Completion date
2024-01-31
Last updated
2018-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

Deep Serratus Block, Reconstructive Breast Surgery, Superficial Serratus block

Brief summary

The novel introduction of various chest wall blocks such as the Pecs I and II/modified Pecs blocks as well as the Serratus Anterior Plane Block have extended the application of perioperative regional anesthesia to provide analgesia for breast surgery. However, to our knowledge, there are no large studies that truly delineate the optimal injection site for the Serratus Anterior Plane Block.

Detailed description

Analgesia for reconstructive breast surgery can be a challenging undertaking; these women have often been through painful mastectomy procedures coupled with the mental and physical discomfort of chemotherapy and its attendant side effects. Additionally, the surgery itself can provoke significant pain; often requiring extensive dissection of soft tissue and muscle to provide flap coverage as well the real discomfort of tissue expansion. The literature has described 2 possible injection sites for the Serratus Anterior Block, however, no study has defined optimal location based on analgesia and duration. Patients will be randomized to receive a deep Serratus Anterior Block (DSAB) where local anesthetic is deposited deep to the serratus or a superficial Serratus Anterior Block (SSAB) where the local anesthetic is placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting.

Interventions

DRUGBupivacaine

20-60cc of 0.25% Bupivacaine

DRUGDexamethasone

2-4mg of Dexamethasone

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

There has been no large, randomized study to define optimal location of injection based on analgesia and duration. Patients will be randomized to receive a deep Serratus Anterior Block (DSAB) where local anesthetic is deposited deep to the serratus or a superficial Serratus Anterior Block (SSAB) where the local anesthetic is placed between serratus and latissimus dorsi.

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients undergoing reconstructive breast surgery

Exclusion criteria

* Patients with allergies to the local anesthetic * Patients who do no consent to regional anesthesia * Patients in which serratus block would be contraindicated * Patients whose anatomy preclude placement of the block

Design outcomes

Primary

MeasureTime frameDescription
Total Pain Scorebaseline to 48 hrs postoperativelyCollection of pain scores (VAS) until approximately 48 hours post-operatively

Secondary

MeasureTime frameDescription
Average Opioid consumption48 hrs postoperativelyAverage opioid consumption 48hrs postoperatively between study group and control
Length of Staybaseline to 72 hrs post-operativelyNumber of days in the hospital
PONV Medicationsbaseline to 48 hrs post-operativelyMean time onset use of rescue PONV medications postoperatively

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026